Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
The recent discovery of mutations of the gene calreticulin has allowed raising the proportion of patients with essential thrombocythemia and primary myelofibrosis with known mutational abnormality up to 85-90%. Knowledge of the mechanisms by which mutated calreticulin underlie a myeloproliferative neoplasm as well as the clinical and therapeutic implications is just at the very beginning, and exciting times await research in this field.
Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Paola
P
Guglielmelli
Niccolò
N
Bartalucci
Giada
G
Rotunno
Alessandro M
AM
Vannucchi
D037282:Calreticulin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000628:therapy*; D055728:Primary Myelofibrosis / Q000235:genetics / Q000628:therapy*; D013920:Thrombocythemia, Essential / Q000235:genetics / Q000628:therapy*
D037282:Calreticulin
JAK/STAT signaling; calreticulin; essential thrombocythemia; myeloproliferative neoplasms; primary myelofibrosis